Izrael - angličtina - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - lenalidomide - hard capsule - lenalidomide 10 mg - lenalidomide - multiple myeloma (mm)lenalidomide s.k. is indicated for the treatment of multiple myeloma. myelodysplastic syndromes lenalidomide s.k. is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. lenalidomide s.k. 7.5 mg is not indicated for treatment in mds. mantle cell lymphoma lenalidomide s.k. is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl). follicular lymphomalenalidomide s.k. in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Izrael - angličtina - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - lenalidomide - hard capsule - lenalidomide 2.5 mg - lenalidomide - multiple myeloma (mm)lenalidomide s.k. is indicated for the treatment of multiple myeloma. myelodysplastic syndromes lenalidomide s.k. is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. lenalidomide s.k. 7.5 mg is not indicated for treatment in mds. mantle cell lymphoma lenalidomide s.k. is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl). follicular lymphomalenalidomide s.k. in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Izrael - angličtina - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - lenalidomide - hard capsule - lenalidomide 25 mg - lenalidomide - multiple myeloma (mm)lenalidomide s.k. is indicated for the treatment of multiple myeloma. myelodysplastic syndromes lenalidomide s.k. is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. lenalidomide s.k. 7.5 mg is not indicated for treatment in mds. mantle cell lymphoma lenalidomide s.k. is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl). follicular lymphomalenalidomide s.k. in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Izrael - angličtina - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - lenalidomide - hard capsule - lenalidomide 5 mg - lenalidomide - multiple myeloma (mm)lenalidomide s.k. is indicated for the treatment of multiple myeloma. myelodysplastic syndromes lenalidomide s.k. is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. lenalidomide s.k. 7.5 mg is not indicated for treatment in mds. mantle cell lymphoma lenalidomide s.k. is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl). follicular lymphomalenalidomide s.k. in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Izrael - angličtina - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - lenalidomide - hard capsule - lenalidomide 7.5 mg - lenalidomide - multiple myeloma (mm)lenalidomide s.k. is indicated for the treatment of multiple myeloma. myelodysplastic syndromes lenalidomide s.k. is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. lenalidomide s.k. 7.5 mg is not indicated for treatment in mds. mantle cell lymphoma lenalidomide s.k. is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl). follicular lymphomalenalidomide s.k. in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Izrael - angličtina - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - lenalidomide - hard capsule - lenalidomide 15 mg - lenalidomide - multiple myeloma (mm)lenalidomide s.k. is indicated for the treatment of multiple myeloma. myelodysplastic syndromes lenalidomide s.k. is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. lenalidomide s.k. 7.5 mg is not indicated for treatment in mds. mantle cell lymphoma lenalidomide s.k. is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl). follicular lymphomalenalidomide s.k. in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Izrael - angličtina - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - lenalidomide - hard capsule - lenalidomide 20 mg - lenalidomide - multiple myeloma (mm)lenalidomide s.k. is indicated for the treatment of multiple myeloma. myelodysplastic syndromes lenalidomide s.k. is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. lenalidomide s.k. 7.5 mg is not indicated for treatment in mds. mantle cell lymphoma lenalidomide s.k. is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl). follicular lymphomalenalidomide s.k. in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

te arai biofarma limited - lenalidomide 2.5mg - capsule - 2.5 mg - active: lenalidomide 2.5mg excipient: allura red ac brilliant blue fcf croscarmellose sodium erythrosine gelatin iron oxide red iron oxide yellow lactose magnesium stearate microcrystalline cellulose titanium dioxide - lenalidomide te arai is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

te arai biofarma limited - lenalidomide 20mg - capsule - 20 mg - active: lenalidomide 20mg excipient: allura red ac brilliant blue fcf croscarmellose sodium gelatin iron oxide red iron oxide yellow lactose magnesium stearate microcrystalline cellulose titanium dioxide - lenalidomide te arai is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

te arai biofarma limited - lenalidomide 7.5mg - capsule - 7.5 mg - active: lenalidomide 7.5mg excipient: brilliant blue fcf croscarmellose sodium erythrosine gelatin lactose magnesium stearate microcrystalline cellulose sunset yellow fcf titanium dioxide - lenalidomide te arai is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.